Vismodegib in the treatment of patients with metastatic basal cell carcinoma (mBCC) and distant metastases: Survival in the pivotal phase II and phase I studies.
Karl D. Lewis
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
Research Funding - Roche/Genentech
Aleksandar Sekulic
Consultant or Advisory Role - Roche/Genentech
Axel Hauschild
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; MedImmune; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; MedImmune; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche
Research Funding - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; MedImmune; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche
Michael Robert Migden
Consultant or Advisory Role - Genentech
Research Funding - Genentech
Anthony E. Oro
No relevant relationships to disclose
Patricia LoRusso
No relevant relationships to disclose
Charles M. Rudin
Consultant or Advisory Role - AVEO; Celgene; Merck
Luc Dirix
No relevant relationships to disclose
James A. Solomon
Consultant or Advisory Role - Genentech
Research Funding - Genentech
John D. Hainsworth
Research Funding - Genentech
Sarah Williams
Employment or Leadership Position - Roche Products Ltd
Jeannie Hou
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Daniel D. Von Hoff
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
Research Funding - Roche